Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ziprasidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 13/20 | 1.00 |
| ▸ | DRD2 known ✓ | P14416 | 11/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 8/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | GOT1 | P17174 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ziprasidone SCHEMBL28028 | 1.00 | HTR2A (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL29368426 | 1.00 | HTR2A (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL30354044 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL3139060 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL122876 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL5859456 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL3143295 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL4914143 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL6599516 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL374870 | 0.99 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012163990-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS TREATED WITH NEUROLEPTIC AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | WO | disclosed |
| EP-1758600-A4 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MAN SCIENCES LLC (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1890700-A2 | METHODS AND COMPOSITIONS FOR MANAGING PSYCHOTIC DISORDERS | Orexigen Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1758600-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | Mood Management Sciences, LLC (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006130522-A2 | METHODS AND COMPOSITIONS FOR MANAGING PSYCHOTIC DISORDERS | OREXIGEN THERAPEUTICS, INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| EP-1663166-A2 | SUSTAINED RELEASE DOSAGE FORMS OF ZIPRASIDONE | Ahmed, Imran (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005120523-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MANAGEMENT SCIENCES, LLC (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005020929-A2 | SUSTAINED RELEASE DOSAGE FORMS OF ZIPRASIDONE | AHMED IMRAN (US) | 2005-03-10 | — | — | WO | disclosed |